Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | PARL | Q9H300 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278809 | 0.83 | MEN1 (0.54) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL7491164 | 0.79 | PARL (0.42) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL22578469 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAPKMPARLPIK3CD | |
| SCHEMBL29236508 | 0.79 | PARL (0.42) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL12266126 | 0.76 | PARL (0.43) | ALDH1A1MAPTPKMPARLPIK3CD | |
| SCHEMBL15614518 | 0.76 | TSHR (0.41) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL13469349 | 0.75 | GRM4 (0.50) | ALDH1A1LMNASMN1; SMN2MAPTPKM | |
| SCHEMBL1939811 | 0.73 | KMT2A (0.53) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1663043 | 0.71 | F2 (0.35) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL27430260 | 0.69 | ALDH1A1 (0.50) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2330909-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8383635-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383635-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383635-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2330909-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2010019637-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136838-A1 | CHEMICAL COMPOUNDS | PDK1, PDK4, PDK3 | ALDH1A1 572/4885LMNA 4436/4885SMN1; SMN2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.